SMARCA4-DEFICIENT MALIGNANT TUMOR
Clinical trials for SMARCA4-DEFICIENT MALIGNANT TUMOR explained in plain language.
Never miss a new study
Get alerted when new SMARCA4-DEFICIENT MALIGNANT TUMOR trials appear
Sign up with your email to follow new studies for SMARCA4-DEFICIENT MALIGNANT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for rare childhood tumors
Disease control OngoingThis phase 2 trial is testing two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with rare INI1-negative cancers that have come back or not responded to treatment. The study aims to see if the combination can shrink tumors or slow disease progression.…
Matched conditions: SMARCA4-DEFICIENT MALIGNANT TUMOR
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail targets childhood cancers with missing proteins
Disease control OngoingThis study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being…
Matched conditions: SMARCA4-DEFICIENT MALIGNANT TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC